BioSpace News Archive

CytoSorbents Corporation reported unaudited financial and operating results for the quarter ended June 30, 2023.

Amygdala Neurosciences has been awarded a $2.0 million NIH grant to support the project titled “Investigational New Drug -enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder.”

Guardant Health, Inc. announced an agreement with Illumina Inc., a global leader in DNA sequencing and array-based technologies, that resolves their pending litigation and promotes a shared resolution to advance the companies’ long-term, commercial partnership.

Varex Imaging Corporation announced its unaudited financial results for the third quarter of fiscal year 2023.

Sangamo Therapeutics, Inc., a genomic medicine company, announced that the company has scheduled the release of its second quarter 2023 financial results after the market closes on Tuesday, August 8, 2023.

STERIS plc announced financial results for its fiscal 2024 first quarter ended June 30, 2023.

Zentalis® Pharmaceuticals, Inc. announced that on August 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 275,000 shares of the Company’s common stock to one newly hired employee.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted Ellen Snow, Akebia’s newly-hired Senior Vice President, Chief Financial Officer and Treasurer, options to purchase 560,000 shares of Akebia’s common stock on July 31, 2023.

ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of July 31, 2023, grants of non-qualified stock options to purchase an aggregate of 20,600 shares of its common stock and restricted stock units covering 10,300 shares of its common stock under the Inducement Plan to two new employees.

Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, announced that it will publish financial results for the second quarter 2023 and provide a business update on August 4, 2023.